EGFR and lung adenocarcinoma: An approximately 30% of advanced lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) mutations [3] benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs) [4, 5].